@FierceBiotech: Ignyta, Lieden University team on rheumatoid arthritis biomarker research. Item | Release | Follow @FierceBiotech
@JohnCFierce: Sarepta spikes on disputed report of adverse events for rival GSK drug. Story | Follow @JohnCFierce
@RyanMFierce: Is Africa poised to play a bigger role in drug innovation? From Novartis: More | Follow @RyanMFierce
> Dutch biotech Dezima Pharma--which is working on developing new drugs in the field of dyslipidemia--raised a total of €14.2 million ($18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995) along with earlier-stage dyslipidemia assets. The A round was led by Forbion Capital Partners and BioGeneration Ventures, with participation from New Science Ventures. The company also gained a €4.4 million loan from an agency of the Dutch Ministry of Economic Affairs. Release
> Cambridge,MA-based Aveo ($AVEO) and its partner Astellas say they will have a May 2 FDA advisory committee review of its advanced renal cell carcinoma therapy tivozanib. Tivozanib has garnered mixed data in late-stage studies which will likely provide plenty of fodder for questions. Story
> Innovus Pharmaceuticals says it has signed a deal with Centric Research Institute for over $7.5 US million in upfront, milestones and sales royalty payments in order to acquire global ex- U.S. rights to the marketed skin cream, CIRCUMserum. Release
Pharma News
@FiercePharma: Trending: Top 10 Pharma Advertising Budgets - 2012. Special Report | Follow @FiercePharma
@EricPFierce: U.S. Supreme Court ruling against Amgen in class action investor case seen as hit to Pharma, other businesses. Story | Follow @EricPFierce
> Ex-Pfizer chief takes helm as Optimer puts out for-sale sign. Story
> Bayer bucks pharma trend with 'remarkable' growth in new drugs. Article
> Mylan eyes injectables domination with $1.6B Agila buy. News
@FierceMedDev: FDA: Spending cuts will delay product approvals. Item | Follow @FierceMedDev
@MarkHFierce: Fierce 15 company CardioKinetix nailed down the second half of a $44M Series E. News | Follow @MarkHFierce
@DamianFierce: Have a look at @FierceMedDev's top 10 moneymakers in medical devices. Special Report | Follow @DamianFierce
> Medtronic scores CE mark for novel TAVI valve. News
> Sorin commits $5M more to Israeli heart failure device startup, with option to buy. More
> Natus predicts 20% revenue soar in 2013. Article
Vaccines News
> FDA panel endorses quadrivalents, setting stage for new flu market. Article
> Is it too soon to quit on Nabi's nicotine vaccine? More
> Seasonal flu vaccine only 56% effective. Story
> GSK facing competition from Sanofi's 6-in-1 shot. Item
> After rejection, Dynavax to shoot for limited hep B vaccine approval. Report
Pharma Manufacturing News
> Ranbaxy problems overshadow manufacturing expansion. Article
> Qualicaps adds new technology as part of expansion. Item
> FDA warning to Abbey questions quality of API for sterile drugs. Story
> Hospira manufacturing problems arise at an inopportune time. More
And Finally… Alarmed by a spike in the number of antibiotic-resistant superbugs in the U.S., health officials have been issuing new warnings to hospitals and other likely breeding grounds for particularly dangerous variants. Story